In addition, we highlight recent advances in tumor microenvironment-targeted therapies for ovarian cancer, focusing on strategies that modulate non-lymphoid components such as cancer-associated fibroblasts (CAFs), hypoxia-driven signaling, and the PI3K/AKT/mTOR axis to enhance antitumor immune responsiveness. The gene discussed is MTOR; the disease is ovarian cancer.